{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:16:05Z","timestamp":1793765765560,"version":"4.6.1"},"reference-count":301,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Immunotherapy, defined as strategies that enhance host antitumor immunity by activating innate and adaptive immune responses, has demonstrated remarkable efficacy in hematologic malignancies. However, its application in solid tumors, particularly those affecting the central nervous system (CNS) such as gliomas, brain metastases, primary CNS lymphoma (PCNSL), and medulloblastomas, has been considerably slower. Major barriers to immunotherapy in these contexts include the physical and functional constraints imposed by the blood-brain barrier (BBB), tumor immune evasion, immunosuppressive microenvironments, tumor heterogeneity, and therapeutic resistance. Emerging consensus challenges the traditional notion of CNS immune privilege, recognizing that distinct anatomical sites within the CNS\u2014including the brain parenchyma, meninges, choroid plexus, perivascular spaces, and calvarial bone marrow\u2014exert diverse immunological functions that modulate local and systemic immunity. This review comprehensively summarizes the immune landscape of different CNS compartments and its impact on immunotherapeutic efficacy, delves into the mechanisms of immune evasion and suppression in CNS, reviews the clinical trials conducted on immunotherapy for CNS tumors, meticulously analyzes the factors contributing to the variability in the efficacy of different immunotherapy modalities across various CNS tumors, critically evaluates current challenges in CNS tumor immunotherapy, and highlights innovative strategies including genomics- and immune profiling-guided personalized immunotherapies, combination regimens integrating immunomodulation with conventional treatments, and novel delivery approaches to overcome the BBB. Our aim is to provide an integrated theoretical framework and forward-looking perspectives to facilitate translational advances and optimize precision immunotherapy for CNS tumors.<\/jats:p>","DOI":"10.1097\/js9.0000000000002993","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:02:43Z","timestamp":1753257763000},"page":"8301-8335","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Immunotherapy in central nervous system tumors"],"prefix":"10.1097","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2433-8183","authenticated-orcid":false,"given":"Yutao","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine UESTC, University of Electronic Science and Technology of China, Mianyang, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingJing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Fifth People\u2019s Hospital of Ningxia Hui Autonomous Region, Shizuishan, Ningxia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine UESTC, University of Electronic Science and Technology of China, Mianyang, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Jin","sequence":"additional","affiliation":[{"name":"The Fifth People\u2019s Hospital of Ningxia Hui Autonomous Region, Shizuishan, Ningxia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9991-6358","authenticated-orcid":false,"given":"Liangxue","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, China"},{"name":"Department of Neurosurgery, NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine UESTC, University of Electronic Science and Technology of China, Mianyang, Sichuan, China"},{"name":"Department of Neurosurgery, The Fifth People\u2019s Hospital of Ningxia Hui Autonomous Region, Shizuishan, Ningxia, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"R1-20260512","first-page":"337\u201341","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nat"},{"key":"R2-20260512","doi-asserted-by":"crossref","first-page":"2316\u201334","DOI":"10.1111\/jnc.16106","article-title":"Infiltration of immune cells to the brain and its relation to the pathogenesis of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"168","author":"Netzahualcoyotzi","year":"2024","journal-title":"J Neurochem"},{"key":"R3-20260512","doi-asserted-by":"crossref","first-page":"eabo7649","DOI":"10.1126\/science.abo7649","article-title":"Transforming the understanding of brain immunity","volume":"380","author":"Castellani","year":"2023","journal-title":"Science"},{"key":"R4-20260512","doi-asserted-by":"crossref","first-page":"417\u201329","DOI":"10.1038\/s41586-022-05474-7","article-title":"Brain borders at the central stage of neuroimmunology","volume":"612","author":"Rustenhoven","year":"2022","journal-title":"Nature"},{"key":"R5-20260512","doi-asserted-by":"crossref","first-page":"439\u201348","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"R6-20260512","first-page":"2548\u201360","article-title":"Current Progress in CAR-T Cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Bio Sci"},{"key":"R7-20260512","doi-asserted-by":"crossref","first-page":"ltab004","DOI":"10.1093\/immadv\/ltab004","article-title":"An overview of CAR T-cell clinical trial activity to 2021","volume":"1","author":"Adami","year":"2021","journal-title":"Immunother Adv"},{"key":"R8-20260512","doi-asserted-by":"crossref","first-page":"91779\u201394","DOI":"10.18632\/oncotarget.21586","article-title":"Recurrent glioma clinical trial, CheckMate-143: the game is not over yet","volume":"8","author":"Filley","year":"2017","journal-title":"Oncotarget"},{"key":"R9-20260512","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Trans Med"},{"key":"R10-20260512","doi-asserted-by":"crossref","first-page":"841\u201345","DOI":"10.1126\/science.1194637","article-title":"Fate mapping analysis reveals that adult microglia derive from primitive macrophages","volume":"330","author":"Ginhoux","year":"2010","journal-title":"Science"},{"key":"R11-20260512","doi-asserted-by":"crossref","first-page":"4216\u201333","DOI":"10.1523\/JNEUROSCI.3441-12.2013","article-title":"Microglia regulate the number of neural precursor cells in the developing cerebral cortex","volume":"33","author":"Cunningham","year":"2013","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"R12-20260512","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cell.2020.05.050","article-title":"Microglial remodeling of the extracellular matrix promotes synapse plasticity","volume":"182","author":"Nguyen","year":"2020","journal-title":"Cell"},{"key":"R13-20260512","doi-asserted-by":"crossref","first-page":"292\u2013311","DOI":"10.1016\/j.cell.2019.08.053","article-title":"Microglia biology: one century of evolving concepts","volume":"179","author":"Prinz","year":"2019","journal-title":"Cell"},{"key":"R14-20260512","doi-asserted-by":"crossref","first-page":"964898","DOI":"10.3389\/fimmu.2022.964898","article-title":"Tumor-associated microglia and macrophages in glioblastoma: from basic insights to therapeutic opportunities","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"R15-20260512","doi-asserted-by":"crossref","first-page":"15612","DOI":"10.3390\/ijms232415612","article-title":"Microglia and brain macrophages as drivers of glioma progression","volume":"23","author":"Zheng","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R16-20260512","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40478-021-01156-z","article-title":"Macrophages and microglia: the cerberus of glioblastoma","volume":"9","author":"Buonfiglioli","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"R17-20260512","first-page":"vdab096","article-title":"Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas","volume":"3","author":"Keane","year":"2021","journal-title":"Neurooncol Adv"},{"key":"R18-20260512","first-page":"779\u201386","article-title":"Microglial immune checkpoint mechanisms","volume":"21","author":"Deczkowska","year":"2018","journal-title":"Nat Neurosci"},{"key":"R19-20260512","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.cell.2020.06.026","article-title":"Microglia require CD4 T Cells to complete the fetal-to-adult transition","volume":"182","author":"Pasciuto","year":"2020","journal-title":"Cell"},{"key":"R20-20260512","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.immuni.2020.11.005","article-title":"Comprehensive profiling of an aging immune system reveals clonal GZMK(+) CD8(+) T cells as conserved hallmark of inflammaging","volume":"54","author":"Mogilenko","year":"2021","journal-title":"Immunity"},{"key":"R21-20260512","doi-asserted-by":"crossref","first-page":"8509\u201321","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: a review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"R22-20260512","doi-asserted-by":"crossref","first-page":"1647\u201357","DOI":"10.1093\/neuonc\/noac055","article-title":"T lymphocytes as dynamic regulators of glioma pathobiology","volume":"24","author":"Cordell","year":"2022","journal-title":"Neuro-oncol"},{"key":"R23-20260512","doi-asserted-by":"crossref","first-page":"74\u201385","DOI":"10.1093\/jnen\/nlz119","article-title":"PD-L1 Expression in pediatric low-grade gliomas is independent of BRAF V600E mutational status","volume":"79","author":"Martin","year":"2020","journal-title":"J Neuropathol Exp Neurol"},{"key":"R24-20260512","doi-asserted-by":"crossref","first-page":"2601\u201316","DOI":"10.1007\/s00262-021-02872-0","article-title":"Regulatory T cells promote glioma cell stemness through TGF-\u03b2-NF-\u03baB-IL6-STAT3 signaling","volume":"70","author":"Liu","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"R25-20260512","doi-asserted-by":"crossref","first-page":"eaay5199","DOI":"10.1126\/sciimmunol.aay5199","article-title":"Meningeal \u03b3\u03b4 T cell-derived IL-17 controls synaptic plasticity and short-term memory","volume":"4","author":"Ribeiro","year":"2019","journal-title":"Sci Immunol"},{"key":"R26-20260512","doi-asserted-by":"crossref","first-page":"1421\u201329","DOI":"10.1038\/s41590-020-0776-4","article-title":"Meningeal \u03b3\u03b4 T cells regulate anxiety-like behavior via IL-17a signaling in neurons","volume":"21","author":"Alves de Lima","year":"2020","journal-title":"Nat Immunol"},{"key":"R27-20260512","doi-asserted-by":"crossref","first-page":"357\u201367","DOI":"10.1215\/15228517-2008-111","article-title":"Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma","volume":"11","author":"Bryant","year":"2009","journal-title":"Neuro-oncol"},{"key":"R28-20260512","doi-asserted-by":"crossref","first-page":"1273986","DOI":"10.3389\/fimmu.2023.1273986","article-title":"\u03b3\u03b4 T cells as a potential therapeutic agent for glioblastoma","volume":"14","author":"Kang","year":"2023","journal-title":"Front Immunol"},{"key":"R29-20260512","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.3390\/cancers15245784","article-title":"The role of \u03b3\u03b4 T-Lymphocytes in glioblastoma: current trends and future directions","volume":"15","author":"Ahmedna","year":"2023","journal-title":"Cancers"},{"key":"R30-20260512","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12672-023-00770-8","article-title":"Classification and function of \u03b3\u03b4T cells and its research progress in anti-glioblastoma","volume":"14","author":"Zhao","year":"2023","journal-title":"Discov Oncol"},{"key":"R31-20260512","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2023.11.032","article-title":"Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma","volume":"187","author":"Kirschenbaum","year":"2024","journal-title":"Cell"},{"key":"R32-20260512","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2019.00555","article-title":"Preferential Infiltration of Unique V\u03b39J\u03b32-V\u03b42 T Cells Into Glioblastoma Multiforme","volume":"10","author":"Lee","year":"2019","journal-title":"Front Immunol"},{"key":"R33-20260512","doi-asserted-by":"crossref","first-page":"336\u201346","DOI":"10.1038\/s41590-020-00860-7","article-title":"Tumor hypoxia represses \u03b3\u03b4 T cell-mediated antitumor immunity against brain tumors","volume":"22","author":"Park","year":"2021","journal-title":"Nat Immunol"},{"key":"R34-20260512","doi-asserted-by":"crossref","first-page":"3660\u201367","DOI":"10.4049\/jimmunol.173.6.3660","article-title":"Fas-Fas ligand interactions are essential for the binding to and killing of activated macrophages by gamma delta T cells","volume":"173","author":"Dalton","year":"2004","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"R35-20260512","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.3389\/fimmu.2019.02044","article-title":"TRAIL-receptor 4 Modulates \u03b3\u03b4 T Cell-cytotoxicity toward cancer cells","volume":"10","author":"Tawfik","year":"2019","journal-title":"Front Immunol"},{"key":"R36-20260512","doi-asserted-by":"crossref","first-page":"2\u20134","DOI":"10.1038\/s41593-020-00749-6","article-title":"Natural killers of cognition","volume":"24","author":"Papismadov","year":"2021","journal-title":"Nat Neurosci"},{"key":"R37-20260512","doi-asserted-by":"crossref","first-page":"1517\u201325","DOI":"10.1038\/s12276-020-00505-7","article-title":"The role of natural killer cells in Parkinson\u2019s disease","volume":"52","author":"Earls","year":"2020","journal-title":"Exp Mol Med"},{"key":"R38-20260512","doi-asserted-by":"crossref","first-page":"194\u2013209","DOI":"10.1016\/j.molmed.2021.12.008","article-title":"NK cells in the brain: implications for brain tumor development and therapy","volume":"28","author":"Balatsoukas","year":"2022","journal-title":"Trends Mol Med"},{"key":"R39-20260512","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3390\/ijms24032111","article-title":"Natural killer cell-based immunotherapy against glioblastoma","volume":"24","author":"Morimoto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R40-20260512","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41531-021-00267-7","article-title":"High neutrophil-to-lymphocyte ratio predicts short survival in multiple system atrophy","volume":"8","author":"Zhang","year":"2022","journal-title":"NPJ Parkinson\u2019s Dis"},{"key":"R41-20260512","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41598-019-57366-y","article-title":"High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis","volume":"10","author":"Choi","year":"2020","journal-title":"Sci Rep"},{"key":"R42-20260512","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3390\/ijms21061954","article-title":"Role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance","volume":"21","author":"Khan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R43-20260512","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3389\/fimmu.2017.01349","article-title":"Neutrophils in Gliomas","volume":"8","author":"Massara","year":"2017","journal-title":"Front Immunol"},{"key":"R44-20260512","doi-asserted-by":"crossref","first-page":"1517\u201330","DOI":"10.1007\/s12035-018-1150-5","article-title":"GBM-Derived Wnt3a Induces M2-Like Phenotype in Microglial Cells Through Wnt\/\u03b2-Catenin Signaling","volume":"56","author":"Matias","year":"2019","journal-title":"Mol Neurobiol"},{"key":"R45-20260512","doi-asserted-by":"crossref","first-page":"e23902","DOI":"10.1371\/journal.pone.0023902","article-title":"Characteristics of the alternative phenotype of microglia\/macrophages and its modulation in experimental gliomas","volume":"6","author":"Gabrusiewicz","year":"2011","journal-title":"PloS One"},{"key":"R46-20260512","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-021-01187-y","article-title":"Neutrophils in cancer carcinogenesis and metastasis","volume":"14","author":"Xiong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R47-20260512","doi-asserted-by":"crossref","first-page":"6992\u20137002","DOI":"10.1158\/1078-0432.CCR-11-1107","article-title":"Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I","volume":"17","author":"Sippel","year":"2011","journal-title":"Clin Cancer Res: Off J American Assoc Cancer Res"},{"key":"R48-20260512","doi-asserted-by":"crossref","first-page":"187\u201398","DOI":"10.1158\/1078-0432.CCR-13-1279","article-title":"Neutrophils promote the malignant glioma phenotype through S100A4","volume":"20","author":"Liang","year":"2014","journal-title":"Clin Cancer Res: Off J American Assoc Cancer Res"},{"key":"R49-20260512","doi-asserted-by":"crossref","first-page":"84\u201388","DOI":"10.1126\/science.adc8810","article-title":"A mesothelium divides the subarachnoid space into functional compartments","volume":"379","author":"M\u00f8llg\u00e5rd","year":"2023","journal-title":"Science"},{"key":"R50-20260512","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cell.2020.12.040","article-title":"Functional characterization of the dural sinuses as a neuroimmune interface","volume":"184","author":"Rustenhoven","year":"2021","journal-title":"Cell"},{"key":"R51-20260512","doi-asserted-by":"crossref","first-page":"3427\u201340","DOI":"10.1093\/brain\/awt259","article-title":"IFN-\u03b3-dependent activation of the brain\u2019s choroid plexus for CNS immune surveillance and repair","volume":"136","author":"Kunis","year":"2013","journal-title":"Brain: J Neurol"},{"key":"R52-20260512","doi-asserted-by":"crossref","first-page":"555\u201369","DOI":"10.1016\/j.immuni.2013.02.012","article-title":"Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus","volume":"38","author":"Shechter","year":"2013","journal-title":"Immunity"},{"key":"R53-20260512","doi-asserted-by":"crossref","first-page":"1529\u201330","DOI":"10.1126\/science.1240514","article-title":"Neuroscience. Garbage truck of the brain","volume":"340","author":"Nedergaard","year":"2013","journal-title":"Science"},{"key":"R54-20260512","doi-asserted-by":"crossref","first-page":"1364\u201382","DOI":"10.1177\/0271678X221098145","article-title":"The meningeal lymphatic vessels and the glymphatic system: potential therapeutic targets in neurological disorders","volume":"42","author":"Li","year":"2022","journal-title":"J Cerebr Blood Flow Metab: Offic J Inter Soc Cerebr Blood Flow Metab"},{"key":"R55-20260512","doi-asserted-by":"crossref","first-page":"5\u201311","DOI":"10.1016\/j.it.2006.11.007","article-title":"What is the blood-brain barrier (not)?","volume":"28","author":"Bechmann","year":"2007","journal-title":"Trends in Immunol"},{"key":"R56-20260512","doi-asserted-by":"crossref","first-page":"62\u201374","DOI":"10.1002\/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S","article-title":"FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier","volume":"27","author":"Bechmann","year":"1999","journal-title":"Glia"},{"key":"R57-20260512","first-page":"627\u201334","article-title":"Fas expression on human fetal astrocytes without susceptibility to fas-mediated cytotoxicity","volume":"84","author":"Becher","year":"1998","journal-title":"Neurosci"},{"key":"R58-20260512","doi-asserted-by":"crossref","first-page":"3096\u201399","DOI":"10.4049\/jimmunol.159.7.3096","article-title":"Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system","volume":"159","author":"Sabelko","year":"1997","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"R59-20260512","doi-asserted-by":"crossref","first-page":"933\u201346","DOI":"10.1083\/jcb.153.5.933","article-title":"Endothelial cell laminin isoforms, laminins 8 and 10, play decisive roles in T cell recruitment across the blood-brain barrier in experimental autoimmune encephalomyelitis","volume":"153","author":"Sixt","year":"2001","journal-title":"J Cell Biol"},{"key":"R60-20260512","doi-asserted-by":"crossref","first-page":"1007\u201319","DOI":"10.1084\/jem.20051342","article-title":"Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis","volume":"203","author":"Agrawal","year":"2006","journal-title":"J Exp Med"},{"key":"R61-20260512","doi-asserted-by":"crossref","first-page":"406\u201315","DOI":"10.1111\/j.1365-2990.1997.tb01315.x","article-title":"Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke","volume":"23","author":"Anthony","year":"1997","journal-title":"Neuropathol Appl Neurobiol"},{"key":"R62-20260512","doi-asserted-by":"crossref","first-page":"1464\u201372","DOI":"10.1093\/brain\/awab388","article-title":"Molecular trans-dural efflux to skull bone marrow in humans with CSF disorders","volume":"145","author":"Ringstad","year":"2022","journal-title":"Brain: J Neurol"},{"key":"R63-20260512","doi-asserted-by":"crossref","first-page":"eabf7844","DOI":"10.1126\/science.abf7844","article-title":"Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma","volume":"373","author":"Cugurra","year":"2021","journal-title":"Science"},{"key":"R64-20260512","doi-asserted-by":"crossref","first-page":"3793\u2013803","DOI":"10.1158\/1078-0432.CCR-20-2188","article-title":"Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through inhibition of apoptosis","volume":"27","author":"Holthof","year":"2021","journal-title":"Clin Cancer Res: Off J American Assoc Cancer Res"},{"key":"R65-20260512","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00262-023-03594-1","article-title":"Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8(+)\u2009clonal effector and CAR T-cell function while promoting a senescence-associated phenotype","volume":"73","author":"Towers","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"R66-20260512","doi-asserted-by":"crossref","first-page":"105568","DOI":"10.1016\/j.ebiom.2025.105568","article-title":"Intracalvariosseous injection: an approach for central nervous system drug delivery through skull bone marrow with a preclinical research in stroke","volume":"112","author":"Liu","year":"2025","journal-title":"EBioMedicine"},{"key":"R67-20260512","doi-asserted-by":"crossref","first-page":"246\u201360","DOI":"10.1016\/S1474-4422(24)00476-9","article-title":"Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease","volume":"24","author":"Pedder","year":"2025","journal-title":"Lancet Neurol"},{"key":"R68-20260512","doi-asserted-by":"crossref","first-page":"1828\u201345","DOI":"10.1002\/cne.25543","article-title":"Estrogenic regulation of claudin 5 and tight junction protein 1 gene expression in zebrafish: a role on blood-brain barrier?","volume":"531","author":"Pellegrini","year":"2023","journal-title":"J Comp Neurol"},{"key":"R69-20260512","doi-asserted-by":"crossref","first-page":"1064\u201378","DOI":"10.1016\/j.cell.2015.10.067","article-title":"Establishment and dysfunction of the blood-brain barrier","volume":"163","author":"Zhao","year":"2015","journal-title":"Cell"},{"key":"R70-20260512","doi-asserted-by":"crossref","first-page":"26\u201341","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R71-20260512","doi-asserted-by":"crossref","first-page":"696\u2013714","DOI":"10.1038\/s41571-021-00529-6","article-title":"The blood-tumour barrier in cancer biology and therapy","volume":"18","author":"Steeg","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R72-20260512","doi-asserted-by":"crossref","first-page":"e163446","DOI":"10.1172\/JCI163446","article-title":"Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy","volume":"133","author":"Khan","year":"2023","journal-title":"J Clin Invest"},{"key":"R73-20260512","doi-asserted-by":"crossref","first-page":"874589","DOI":"10.3389\/fimmu.2022.874589","article-title":"Tumor-associated macrophages regulate PD-1\/PD-L1 Immunosuppression","volume":"13","author":"Pu","year":"2022","journal-title":"Front Immunol"},{"key":"R74-20260512","doi-asserted-by":"crossref","first-page":"e009930","DOI":"10.1136\/jitc-2024-009930","article-title":"Arginase-1-specific T cells target and modulate tumor-associated macrophages","volume":"13","author":"Martinenaite","year":"2025","journal-title":"J Immunother Cancer"},{"key":"R75-20260512","doi-asserted-by":"crossref","first-page":"1739\u201348","DOI":"10.1111\/1759-7714.15398","article-title":"PRPS2-mediated modulation of the antitumor immune response in lung cancer through CCL2-mediated tumor-associated macrophages and myeloid-derived suppressor cells","volume":"15","author":"Liu","year":"2024","journal-title":"Thorac Cancer"},{"key":"R76-20260512","doi-asserted-by":"crossref","first-page":"110830","DOI":"10.1016\/j.isci.2024.110830","article-title":"CXCR4-enriched T regulatory cells preferentially home to bone marrow and resolve inflammation","volume":"27","author":"Huang","year":"2024","journal-title":"iScience"},{"key":"R77-20260512","doi-asserted-by":"crossref","first-page":"647\u201358","DOI":"10.1007\/s11060-024-04766-4","article-title":"The CCL2-CCR4 axis promotes regulatory T cell trafficking to canine glioma tissues","volume":"169","author":"Panek","year":"2024","journal-title":"J Neuro-oncol"},{"key":"R78-20260512","doi-asserted-by":"crossref","first-page":"919674","DOI":"10.3389\/fimmu.2022.919674","article-title":"TGF-\u03b2 enhances immunosuppression of myeloid-derived suppressor cells to induce transplant immune tolerance through affecting Arg-1 Expression","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"R80-20260512","doi-asserted-by":"crossref","first-page":"112922","DOI":"10.1016\/j.intimp.2024.112922","article-title":"Immunosuppressive MDSC and Treg signatures predict prognosis and therapeutic response in glioma","volume":"141","author":"Yin","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R81-20260512","doi-asserted-by":"crossref","first-page":"1574\u201380","DOI":"10.1038\/jid.2015.26","article-title":"CCL22 to activate treg migration and suppress depigmentation in vitiligo","volume":"135","author":"Eby","year":"2015","journal-title":"J Invest Dermatol"},{"key":"R82-20260512","first-page":"790\u2013801","article-title":"Single-cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent Glioblastoma","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Genet Ther"},{"key":"R83-20260512","doi-asserted-by":"crossref","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"R84-20260512","doi-asserted-by":"crossref","first-page":"450\u201365","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"R85-20260512","doi-asserted-by":"crossref","first-page":"1002\u201322","DOI":"10.1038\/s41423-023-01036-7","article-title":"Intricacies of TGF-\u03b2 signaling in Treg and Th17 cell biology","volume":"20","author":"Wang","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"R86-20260512","doi-asserted-by":"crossref","first-page":"195\u2013205","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro-oncol"},{"key":"R87-20260512","doi-asserted-by":"crossref","first-page":"2143\u201350","DOI":"10.1111\/1759-7714.14006","article-title":"Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications","volume":"12","author":"Lee","year":"2021","journal-title":"Thorac Cancer"},{"key":"R88-20260512","doi-asserted-by":"crossref","first-page":"24\u201335","DOI":"10.1016\/j.ejca.2021.02.005","article-title":"Post-progression outcomes of NSCLC patients with PD-L1 expression \u2265 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study","volume":"148","author":"Cortellini","year":"2021","journal-title":"Eur J Cancer"},{"key":"R89-20260512","doi-asserted-by":"crossref","first-page":"281\u201391","DOI":"10.1007\/s11060-018-2886-5","article-title":"PD-1\/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population","volume":"139","author":"Hwang","year":"2018","journal-title":"J Neuro-oncol"},{"key":"R90-20260512","doi-asserted-by":"crossref","first-page":"1461\u201364","DOI":"10.1002\/pbc.26018","article-title":"Low frequency of programmed death ligand 1 expression in pediatric cancers","volume":"63","author":"Aoki","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R91-20260512","doi-asserted-by":"crossref","first-page":"5632\u201334","DOI":"10.1016\/j.asjsur.2023.08.057","article-title":"Meta-analysis of the correlation between glioma prognosis and PD-1\/PD-L1 expression","volume":"46","author":"Ren","year":"2023","journal-title":"Asian J Surg"},{"key":"R92-20260512","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12885-020-06755-y","article-title":"PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma","volume":"20","author":"Furuse","year":"2020","journal-title":"BMC Cancer"},{"key":"R93-20260512","doi-asserted-by":"crossref","first-page":"1561388","DOI":"10.3389\/fimmu.2025.1561388","article-title":"Single-cell and spatial transcriptomic insights into glioma cellular heterogeneity and metabolic adaptations","volume":"16","author":"Fu","year":"2025","journal-title":"Front Immunol"},{"key":"R94-20260512","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-017-0455-6","article-title":"Blocking the PD-1\/PD-L1 pathway in glioma: a potential new treatment strategy","volume":"10","author":"Xue","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R95-20260512","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fnmol.2018.00082","article-title":"The IDH1 mutation-induced oncometabolite, 2-hydroxyglutarate, may affect dna methylation and expression of PD-L1 in gliomas","volume":"11","author":"Mu","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"R96-20260512","doi-asserted-by":"crossref","first-page":"2271\u201380","DOI":"10.1007\/s00432-021-03656-w","article-title":"Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma","volume":"147","author":"H\u00f6lzl","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"R97-20260512","doi-asserted-by":"crossref","first-page":"P221","DOI":"10.1186\/2051-1426-2-S3-P221","article-title":"PD-1\/SHP-2 negatively regulate Tc1\/Th1 phenotypic responses and activation of T cells in the tumor microenvironment","volume":"2","author":"Li","year":"2014","journal-title":"J Immunother Cancer"},{"key":"R98-20260512","first-page":"508\u201318","article-title":"PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res"},{"key":"R99-20260512","doi-asserted-by":"crossref","first-page":"1391\u201399","DOI":"10.1038\/bjc.2014.416","article-title":"PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients","volume":"111","author":"Wu","year":"2014","journal-title":"Br J Cancer"},{"key":"R100-20260512","doi-asserted-by":"crossref","first-page":"E2480","DOI":"10.1073\/pnas.1305394110","article-title":"Strength of PD-1 signaling differentially affects T-cell effector functions","volume":"110","author":"Wei","year":"2013","journal-title":"Proc Natl Acad Sci"},{"key":"R101-20260512","doi-asserted-by":"crossref","first-page":"578877","DOI":"10.3389\/fimmu.2020.578877","article-title":"Immune checkpoint targeted therapy in glioma: status and hopes","volume":"11","author":"Qi","year":"2020","journal-title":"Front Immunol"},{"key":"R102-20260512","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12935-019-1085-6","article-title":"CTLA-4 correlates with immune and clinical characteristics of glioma","volume":"20","author":"Liu","year":"2020","journal-title":"Cancer Cell Int"},{"key":"R103-20260512","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/v15051141","article-title":"The Role of CTLA-4 in T cell exhaustion in chronic hepatitis B virus infection","volume":"15","author":"Apol","year":"2023","journal-title":"Viruses"},{"key":"R104-20260512","doi-asserted-by":"crossref","first-page":"2415\u201333","DOI":"10.1084\/jem.20130150","article-title":"Regulated vesicle fusion generates signaling nanoterritories that control T cell activation at the immunological synapse","volume":"210","author":"Soares","year":"2013","journal-title":"J Exp Med"},{"key":"R105-20260512","first-page":"227\u201342","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R106-20260512","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/ijms19041113","article-title":"Differential expression and clinical significance of transforming growth factor-beta isoforms in GBM tumors","volume":"19","author":"Roy","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R107-20260512","doi-asserted-by":"crossref","first-page":"1809\u201318","DOI":"10.1007\/s00262-009-0692-9","article-title":"TGF-\u03b2 modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression","volume":"58","author":"Di Bari","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"R108-20260512","doi-asserted-by":"crossref","first-page":"8\u2013","DOI":"10.1038\/nri1771","article-title":"TGF\u03b2 suppresses cytotoxicity","volume":"6","author":"Honey","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"R109-20260512","doi-asserted-by":"crossref","first-page":"155\u201361","DOI":"10.1248\/bpb.b21-00966","article-title":"TGF-\u03b2 and Cancer Immunotherapy","volume":"45","author":"MaruYama","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"R110-20260512","doi-asserted-by":"crossref","first-page":"694145","DOI":"10.3389\/fonc.2021.694145","article-title":"TGF-\u03b21 induces immune escape by enhancing PD-1 and CTLA-4 expression on T Lymphocytes in hepatocellular carcinoma","volume":"11","author":"Bao","year":"2021","journal-title":"Front Oncol"},{"key":"R111-20260512","doi-asserted-by":"crossref","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci Signaling"},{"key":"R112-20260512","doi-asserted-by":"crossref","first-page":"7335\u201340","DOI":"10.4049\/jimmunol.172.12.7335","article-title":"Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients","volume":"172","author":"Lee","year":"2004","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"R113-20260512","doi-asserted-by":"crossref","first-page":"1239\u201344","DOI":"10.1631\/jzus.2004.1239","article-title":"TGF-beta1 treated murine dendritic cells are maturation resistant and down-regulate Toll-like receptor 4 expression","volume":"5","author":"Mou","year":"2004","journal-title":"J Zhejiang Univ Sci"},{"key":"R114-20260512","doi-asserted-by":"crossref","first-page":"E1480","DOI":"10.1073\/pnas.1615065114","article-title":"TGF-\u03b2 inhibitor Smad7 regulates dendritic cell-induced autoimmunity","volume":"114","author":"Lukas","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"R115-20260512","first-page":"357\u201367","article-title":"Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma","volume":"95","author":"Abad","year":"2014","journal-title":"J Leukoc Biol"},{"key":"R116-20260512","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.3390\/ijms21103599","article-title":"Understanding the differentiation, expansion, recruitment and suppressive activities of myeloid-derived suppressor cells in cancers","volume":"21","author":"Lim","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R117-20260512","doi-asserted-by":"crossref","first-page":"e1490853","DOI":"10.1080\/2162402X.2018.1490853","article-title":"TGF-\u03b21 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy","volume":"7","author":"Jayaraman","year":"2018","journal-title":"Oncoimmunol"},{"key":"R118-20260512","doi-asserted-by":"crossref","first-page":"3321\u201329","DOI":"10.4049\/jimmunol.176.6.3321","article-title":"TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells","volume":"176","author":"Zheng","year":"2006","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"R119-20260512","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R120-20260512","doi-asserted-by":"crossref","first-page":"113089","DOI":"10.1016\/j.intimp.2024.113089","article-title":"Interleukin-10 overexpression in 4T1 cells: a gateway to suppressing mammary carcinoma growth","volume":"142","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R121-20260512","doi-asserted-by":"crossref","first-page":"1644\u201355","DOI":"10.1038\/bjc.2017.336","article-title":"Interleukin-10-regulated tumour tolerance in non-small cell lung cancer","volume":"117","author":"Vahl","year":"2017","journal-title":"Br J Cancer"},{"key":"R122-20260512","doi-asserted-by":"crossref","first-page":"379\u201386","DOI":"10.1016\/j.coph.2006.01.010","article-title":"Understanding and exploiting the endogenous interleukin-10\/STAT3-mediated anti-inflammatory response","volume":"6","author":"Murray","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"R123-20260512","first-page":"58","article-title":"SOCS3, A major regulator of infection and inflammation","volume":"5","author":"Rottenberg","year":"2014","journal-title":"Front Immunol"},{"key":"R124-20260512","doi-asserted-by":"crossref","first-page":"27158\u201367","DOI":"10.1074\/jbc.M115.682708","article-title":"Interleukin 10 (IL-10)-mediated Immunosuppression: MARCH-I INDUCTION REGULATES ANTIGEN PRESENTATION BY MACROPHAGES BUT NOT DENDRITIC CELLS *","volume":"290","author":"Mittal","year":"2015","journal-title":"J Biol Chem"},{"key":"R125-20260512","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fimmu.2020.00083","article-title":"iCa2+ Flux, ROS and IL-10 Determines Cytotoxic, and Suppressor T cell functions in chronic human viral infections","volume":"11","author":"Mohanty","year":"2020","journal-title":"Front Immunol"},{"key":"R126-20260512","doi-asserted-by":"crossref","first-page":"3188\u2013200","DOI":"10.1038\/s41375-021-01217-1","article-title":"Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia","volume":"35","author":"Rivas","year":"2021","journal-title":"Leukemia"},{"key":"R127-20260512","first-page":"552\u201365","article-title":"Nanog promotes stem-like traits of glioblastoma cells","volume":"26","author":"Ye","year":"2021","journal-title":"Fbl"},{"key":"R128-20260512","doi-asserted-by":"crossref","first-page":"2383\u201392","DOI":"10.1002\/stem.185","article-title":"STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells","volume":"27","author":"Sherry","year":"2009","journal-title":"Stem Cells (Dayton, Ohio)"},{"key":"R129-20260512","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3389\/fimmu.2019.01267","article-title":"IL-10\/STAT3\/SOCS3 Axis Is Involved in the Anti-inflammatory effect of benznidazole","volume":"10","author":"Cevey","year":"2019","journal-title":"Front Immunol"},{"key":"R130-20260512","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12950-018-0180-0","article-title":"Interleukin-10 attenuates impairment of the blood-brain barrier in a severe acute pancreatitis rat model","volume":"15","author":"Lin","year":"2018","journal-title":"J Inflam"},{"key":"R131-20260512","doi-asserted-by":"crossref","first-page":"324\u201331","DOI":"10.1016\/j.bbrc.2018.05.140","article-title":"Hypoxic glioblastoma release exosomal VEGF-A induce the permeability of blood-brain barrier","volume":"502","author":"Zhao","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R132-20260512","doi-asserted-by":"crossref","first-page":"7207\u201321","DOI":"10.1002\/cam4.5511","article-title":"Dendritic cell vaccines improve the glioma microenvironment: influence, challenges, and future directions","volume":"12","author":"Zhou","year":"2023","journal-title":"Cancer Med"},{"key":"R133-20260512","doi-asserted-by":"crossref","first-page":"616837","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front Immunol"},{"key":"R134-20260512","doi-asserted-by":"crossref","first-page":"139\u201348","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"R135-20260512","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s12967-024-05907-z","article-title":"Inhibition of VEGF signaling prevents exhaustion and enhances anti-leukemia efficacy of CAR-T cells via Wnt\/\u03b2-catenin pathway","volume":"23","author":"Wu","year":"2025","journal-title":"J Transl Med"},{"key":"R136-20260512","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/cells10102700","article-title":"A complex metabolic network confers immunosuppressive functions to myeloid-derived suppressor cells (MDSCs) within the tumour microenvironment","volume":"10","author":"Hofer","year":"2021","journal-title":"Cells"},{"key":"R137-20260512","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13046-023-02845-4","article-title":"Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity","volume":"42","author":"Zheng","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"R138-20260512","doi-asserted-by":"crossref","first-page":"1371\u201379","DOI":"10.1038\/s12276-023-01028-7","article-title":"Immune regulation through tryptophan metabolism","volume":"55","author":"Seo","year":"2023","journal-title":"Exp Mol Med"},{"key":"R139-20260512","doi-asserted-by":"crossref","first-page":"1426\u201340","DOI":"10.1038\/s41423-024-01230-1","article-title":"Kynurenine-AhR reduces T-cell infiltration and induces a delayed T-cell immune response by suppressing the STAT1-CXCL9\/CXCL10 axis in tuberculosis","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"R140-20260512","doi-asserted-by":"crossref","first-page":"e2012692118","DOI":"10.1073\/pnas.2012692118","article-title":"The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation","volume":"118","author":"Kenison","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"R141-20260512","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41467-019-08887-7","article-title":"The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"R142-20260512","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12974-015-0328-2","article-title":"Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans","volume":"12","author":"Yan","year":"2015","journal-title":"J Neuroinflamm"},{"key":"R143-20260512","doi-asserted-by":"crossref","first-page":"463\u201371","DOI":"10.1038\/npp.2014.194","article-title":"Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder","volume":"40","author":"Savitz","year":"2015","journal-title":"Neuropsychopharmacol: Off Publ Am College of Neuropsychopharmacol"},{"key":"R144-20260512","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3390\/cells13100844","article-title":"Immune cell migration to cancer","volume":"13","author":"Ryan","year":"2024","journal-title":"Cells"},{"key":"R145-20260512","first-page":"2029\u201337","article-title":"The function and mechanism of lactate and lactylation in tumor metabolism and microenvironment","volume":"10","author":"Zhang","year":"2023","journal-title":"Genes Dis"},{"key":"R146-20260512","doi-asserted-by":"crossref","first-page":"932055","DOI":"10.3389\/fimmu.2022.932055","article-title":"Lactate from the tumor microenvironment - A key obstacle in NK cell-based immunotherapies","volume":"13","author":"Jedli\u010dka","year":"2022","journal-title":"Front Immunol"},{"key":"R147-20260512","doi-asserted-by":"crossref","first-page":"103627","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: from immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"key":"R148-20260512","doi-asserted-by":"crossref","first-page":"1563303","DOI":"10.3389\/fimmu.2025.1563303","article-title":"Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives","volume":"16","author":"Gu","year":"2025","journal-title":"Front Immunol"},{"key":"R149-20260512","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","article-title":"Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments","volume":"40","author":"Kumagai","year":"2022","journal-title":"Cancer Cell"},{"key":"R150-20260512","doi-asserted-by":"crossref","first-page":"1208870","DOI":"10.3389\/fimmu.2023.1208870","article-title":"Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy","volume":"14","author":"Tao","year":"2023","journal-title":"Front Immunol"},{"key":"R151-20260512","doi-asserted-by":"crossref","first-page":"110451","DOI":"10.1016\/j.celrep.2022.110451","article-title":"Notch-mediated lactate metabolism regulates MDSC development through the Hes1\/MCT2\/c-Jun axis","volume":"38","author":"Zhao","year":"2022","journal-title":"Cell Rep"},{"key":"R152-20260512","doi-asserted-by":"crossref","first-page":"866\u201368","DOI":"10.1161\/CIRCRESAHA.108.175570","article-title":"Arginine and Arginase","volume":"102","author":"Vanhoutte","year":"2008","journal-title":"Circ Res"},{"key":"R153-20260512","doi-asserted-by":"crossref","first-page":"703465","DOI":"10.3389\/fonc.2021.703465","article-title":"A novel oral arginase 1\/2 inhibitor enhances the antitumor effect of PD-1 inhibition in murine experimental gliomas by altering the immunosuppressive environment","volume":"11","author":"Pilanc","year":"2021","journal-title":"Front Oncol"},{"key":"R154-20260512","doi-asserted-by":"crossref","first-page":"21123\u201329","DOI":"10.1074\/jbc.M110675200","article-title":"Regulation of T cell receptor CD3\u03b6 chain expression byl-arginine*","volume":"277","author":"Rodriguez","year":"2002","journal-title":"J Biol Chem"},{"key":"R155-20260512","doi-asserted-by":"crossref","first-page":"5259\u201367","DOI":"10.4049\/jimmunol.0803523","article-title":"Regulation of NK cell function by human granulocyte arginase","volume":"182","author":"Oberlies","year":"2009","journal-title":"J Immunol (Baltimore, Md: 1950)"},{"key":"R156-20260512","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41419-024-06435-w","article-title":"Amino acid metabolism in tumor biology and therapy","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis"},{"key":"R157-20260512","doi-asserted-by":"crossref","first-page":"844866","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front Immunol"},{"key":"R158-20260512","doi-asserted-by":"crossref","first-page":"871\u201374","DOI":"10.1038\/nature04431","article-title":"The Polycomb group protein EZH2 directly controls DNA methylation","volume":"439","author":"Vir\u00e9","year":"2006","journal-title":"Nature"},{"key":"R159-20260512","doi-asserted-by":"crossref","first-page":"e19139","DOI":"10.1371\/journal.pone.0019139","article-title":"MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1\u03b1 expression","volume":"6","author":"Liu","year":"2011","journal-title":"PloS One"},{"key":"R160-20260512","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12964-021-00816-w","article-title":"Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies","volume":"20","author":"Liu","year":"2022","journal-title":"Cell Commun Signaling"},{"key":"R161-20260512","doi-asserted-by":"crossref","first-page":"1376962","DOI":"10.3389\/fimmu.2024.1376962","article-title":"Extracellular vesicle-mediated communication between CD8+ cytotoxic T cells and tumor cells","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"R162-20260512","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2025.02.043","article-title":"Killing the killers: natural killer cell therapy targeting glioma stem cells in high-grade glioma","author":"Poorva","year":"2025","journal-title":"Mol Ther"},{"key":"R163-20260512","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-025-02233-w","article-title":"Extracellular vesicles in tumor immunity: mechanisms and novel insights","volume":"24","author":"Kuang","year":"2025","journal-title":"Mol Cancer"},{"key":"R164-20260512","doi-asserted-by":"crossref","first-page":"e1362527","DOI":"10.1080\/2162402X.2017.1362527","article-title":"Tumor-derived exosomes educate dendritic cells to promote tumor metastasis via HSP72\/HSP105-TLR2\/TLR4 pathway","volume":"6","author":"Shen","year":"2017","journal-title":"Oncoimmunol"},{"key":"R165-20260512","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell"},{"key":"R166-20260512","doi-asserted-by":"crossref","first-page":"e202451102","DOI":"10.1002\/eji.202451102","article-title":"Metabolic dialogue shapes immune response in the tumor microenvironment","volume":"55","author":"Gao","year":"2025","journal-title":"Eur J Immunol"},{"key":"R167-20260512","doi-asserted-by":"crossref","first-page":"681\u2013702","DOI":"10.1101\/gad.350693.123","article-title":"Metabolic partitioning in the brain and its hijacking by glioblastoma","volume":"37","author":"de Ruiter Swain","year":"2023","journal-title":"Genes Dev"},{"key":"R168-20260512","doi-asserted-by":"crossref","first-page":"987\u201396","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"New Engl J Med"},{"key":"R169-20260512","doi-asserted-by":"crossref","first-page":"2306\u201316","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"Jama"},{"key":"R170-20260512","doi-asserted-by":"crossref","first-page":"1396\u2013401","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"key":"R171-20260512","doi-asserted-by":"crossref","first-page":"12\u201325","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R172-20260512","doi-asserted-by":"crossref","first-page":"2055417","DOI":"10.1080\/21645515.2022.2055417","article-title":"Immunotherapy of glioblastoma: recent advances and future prospects","volume":"18","author":"Yuan","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"R173-20260512","first-page":"2769\u201379","article-title":"Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 Receptor for treatment of high-grade pediatric CNS tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"key":"R174-20260512","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-022-01711-9","article-title":"Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"R175-20260512","doi-asserted-by":"crossref","first-page":"934\u201341","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"R176-20260512","doi-asserted-by":"crossref","first-page":"1320\u201329","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat Med"},{"key":"R177-20260512","first-page":"1001\u201312","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"R178-20260512","doi-asserted-by":"crossref","first-page":"1318\u201330","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro-oncol"},{"key":"R179-20260512","doi-asserted-by":"crossref","first-page":"2561\u201369","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-Cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"New Engl J Med"},{"key":"R180-20260512","doi-asserted-by":"crossref","first-page":"4062\u201372","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and Safety of IL13R\u03b12-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res: Off J American Assoc Cancer Res"},{"key":"R181-20260512","doi-asserted-by":"crossref","first-page":"1544\u201352","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"key":"R182-20260512","first-page":"126\u201335","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T Cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"R183-20260512","doi-asserted-by":"crossref","first-page":"694941","DOI":"10.3389\/fonc.2021.694941","article-title":"First-in-Human Trial of EphA2-Redirected CAR T-Cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"R184-20260512","first-page":"1158\u201366","article-title":"Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients","volume":"24","author":"Guo","year":"2019","journal-title":"Front Biosci (Landmark Edition)"},{"key":"R185-20260512","doi-asserted-by":"crossref","first-page":"3565\u201377","DOI":"10.1158\/1078-0432.CCR-20-0176","article-title":"Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses: results from a Phase I\/II trial","volume":"26","author":"Weathers","year":"2020","journal-title":"Clin Cancer Res: Off J American Assoc Cancer Res"},{"key":"R186-20260512","doi-asserted-by":"crossref","first-page":"256\u201364","DOI":"10.1158\/0008-5472.CAN-17-0469","article-title":"Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma","volume":"78","author":"Reap","year":"2018","journal-title":"Cancer Res"},{"key":"R187-20260512","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41467-018-03217-9","article-title":"Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells","volume":"9","author":"Kirkin","year":"2018","journal-title":"Nat Commun"},{"key":"R188-20260512","doi-asserted-by":"crossref","first-page":"150\u201361","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"New Engl J Med"},{"key":"R189-20260512","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1038\/s41467-024-48073-y","article-title":"TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial","volume":"15","author":"Everson","year":"2024","journal-title":"Nat Commun"},{"key":"R190-20260512","doi-asserted-by":"crossref","first-page":"112\u201321","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"R191-20260512","doi-asserted-by":"crossref","first-page":"e151239","DOI":"10.1172\/JCI151239","article-title":"Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas","volume":"132","author":"Ogino","year":"2022","journal-title":"J Clin Invest"},{"key":"R192-20260512","doi-asserted-by":"crossref","first-page":"5297\u2013303","DOI":"10.1158\/1078-0432.CCR-20-1082","article-title":"Once, twice, three times a finding: reproducibility of dendritic cell vaccine trials targeting cytomegalovirus in glioblastoma","volume":"26","author":"Batich","year":"2020","journal-title":"Clin Cancer Res: Off J American Assoc Cancer Res"},{"key":"R193-20260512","doi-asserted-by":"crossref","first-page":"1375\u201387","DOI":"10.1007\/s00262-020-02496-w","article-title":"Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients","volume":"69","author":"Wang","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"R194-20260512","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3389\/fimmu.2018.00727","article-title":"Predictors of response to autologous dendritic cell therapy in glioblastoma multiforme","volume":"9","author":"Jan","year":"2018","journal-title":"Front Immunol"},{"key":"R195-20260512","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12967-017-1202-z","article-title":"A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients","volume":"15","author":"Inog\u00e9s","year":"2017","journal-title":"J Transl Med"},{"key":"R196-20260512","doi-asserted-by":"crossref","first-page":"1499\u2013509","DOI":"10.1007\/s00262-016-1905-7","article-title":"Phase I\/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma","volume":"65","author":"Akasaki","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"R197-20260512","doi-asserted-by":"crossref","first-page":"366\u201369","DOI":"10.1038\/nature14320","article-title":"Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients","volume":"519","author":"Mitchell","year":"2015","journal-title":"Nature"},{"key":"R198-20260512","doi-asserted-by":"crossref","first-page":"71\u201378","DOI":"10.1007\/s11060-019-03336-3","article-title":"Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy","volume":"146","author":"Alcaide-Leon","year":"2020","journal-title":"J Neuro-oncol"},{"key":"R199-20260512","doi-asserted-by":"crossref","first-page":"331\u201340","DOI":"10.1007\/s00262-018-2274-1","article-title":"A phase I clinical study of a cocktail vaccine of Wilms\u2019 tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma","volume":"68","author":"Tsuboi","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"R200-20260512","doi-asserted-by":"crossref","first-page":"e98791","DOI":"10.1172\/jci.insight.98791","article-title":"Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas","volume":"3","author":"M\u00fcller","year":"2018","journal-title":"JCI Insight"},{"key":"R201-20260512","doi-asserted-by":"crossref","first-page":"1339\u201352","DOI":"10.1007\/s00262-016-1890-x","article-title":"Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma","volume":"65","author":"Fenstermaker","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"R202-20260512","doi-asserted-by":"crossref","first-page":"1391\u2013401","DOI":"10.1002\/ijc.30182","article-title":"Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide","volume":"139","author":"Oji","year":"2016","journal-title":"Int J Cancer"},{"key":"R203-20260512","doi-asserted-by":"crossref","first-page":"1602\u201316","DOI":"10.1093\/neuonc\/noae105","article-title":"Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy","volume":"26","author":"Noh","year":"2024","journal-title":"Neuro-oncol"},{"key":"R204-20260512","doi-asserted-by":"crossref","first-page":"471\u201378","DOI":"10.1016\/S2352-4642(23)00031-7","article-title":"Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial","volume":"7","author":"Thompson","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R205-20260512","doi-asserted-by":"crossref","first-page":"537\u201346","DOI":"10.1093\/neuonc\/noy202","article-title":"Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma","volume":"21","author":"Kieran","year":"2019","journal-title":"Neuro-oncol"},{"key":"R206-20260512","doi-asserted-by":"crossref","first-page":"1137\u201345","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro-oncol"},{"key":"R207-20260512","doi-asserted-by":"crossref","first-page":"951\u201363","DOI":"10.1093\/neuonc\/noab271","article-title":"Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase I trial","volume":"24","author":"Chiocca","year":"2022","journal-title":"Neuro-oncol"},{"key":"R208-20260512","doi-asserted-by":"crossref","first-page":"e002296","DOI":"10.1136\/jitc-2020-002296","article-title":"Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial","volume":"9","author":"Duerinck","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R209-20260512","doi-asserted-by":"crossref","first-page":"632547","DOI":"10.3389\/fimmu.2021.632547","article-title":"Combination of immunotherapy and radiotherapy for recurrent malignant gliomas: results from a prospective study","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"key":"R210-20260512","doi-asserted-by":"crossref","first-page":"eabd0772","DOI":"10.1126\/sciadv.abd0772","article-title":"Neuronavigation-guided focused ultrasound for transcranial blood-brain barrier opening and immunostimulation in brain tumors","volume":"7","author":"Chen","year":"2021","journal-title":"Sci Adv"},{"key":"R211-20260512","doi-asserted-by":"crossref","first-page":"1040\u201350","DOI":"10.1016\/S1470-2045(18)30322-X","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial","volume":"19","author":"Souweidane","year":"2018","journal-title":"Lancet Oncol"},{"key":"R212-20260512","doi-asserted-by":"crossref","first-page":"632\u201342","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"R213-20260512","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"R214-20260512","doi-asserted-by":"crossref","first-page":"2288\u2013301","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"New Engl J Med"},{"key":"R215-20260512","doi-asserted-by":"crossref","first-page":"97\u2013103","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"R216-20260512","doi-asserted-by":"crossref","first-page":"1243\u201350","DOI":"10.1158\/2326-6066.CIR-20-0196","article-title":"The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non\u2013small cell lung cancer","volume":"8","author":"Hakozaki","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"R217-20260512","doi-asserted-by":"crossref","first-page":"498\u2013502","DOI":"10.1016\/j.eururo.2020.07.011","article-title":"Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti\u2013PD-1 immune checkpoint inhibitors","volume":"78","author":"Salgia","year":"2020","journal-title":"Europ Urol"},{"key":"R218-20260512","first-page":"171\u201380","article-title":"Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic\/Tumor Vaccines","volume":"39","author":"Liu","year":"2016","journal-title":"J Immunother (Hagerstown, Md: 1997)"},{"key":"R219-20260512","doi-asserted-by":"crossref","first-page":"108\u201319","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"R220-20260512","doi-asserted-by":"crossref","first-page":"24\u201334","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"New Engl J Med"},{"key":"R221-20260512","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.3390\/cancers13215387","article-title":"Immunotherapy in medulloblastoma: current state of research, challenges, and future perspectives","volume":"13","author":"Voskamp","year":"2021","journal-title":"Cancers"},{"key":"R222-20260512","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","article-title":"Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R223-20260512","doi-asserted-by":"crossref","first-page":"109178","DOI":"10.1016\/j.clim.2022.109178","article-title":"Expression and clinical significance of VISTA, B7-H3, and PD-L1 in glioma","volume":"245","author":"Wang","year":"2022","journal-title":"Clin Immunol (Orlando, Fla)"},{"key":"R224-20260512","doi-asserted-by":"crossref","first-page":"7622\u201334","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"R225-20260512","doi-asserted-by":"crossref","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"EBioMedicine"},{"key":"R226-20260512","first-page":"113\u201317","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nat"},{"key":"R227-20260512","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R228-20260512","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"key":"R229-20260512","doi-asserted-by":"crossref","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunol"},{"key":"R230-20260512","first-page":"1850\u201366","article-title":"IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma","volume":"10","author":"Hou","year":"2024","journal-title":"Neuro-oncol"},{"key":"R231-20260512","doi-asserted-by":"crossref","first-page":"1192\u2013204","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"key":"R232-20260512","first-page":"240\u201345","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nat"},{"key":"R233-20260512","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"key":"R234-20260512","doi-asserted-by":"crossref","first-page":"2969\u201389","DOI":"10.1016\/j.apsb.2022.03.011","article-title":"mRNA cancer vaccines: advances, trends and challenges","volume":"12","author":"He","year":"2022","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"R235-20260512","first-page":"107\u201312","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nat"},{"key":"R236-20260512","doi-asserted-by":"crossref","first-page":"840\u201354","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat Biotechnol"},{"key":"R237-20260512","doi-asserted-by":"crossref","first-page":"134\u201353","DOI":"10.1016\/j.ymthe.2022.08.021","article-title":"CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther: J American Soc Gene Ther"},{"key":"R238-20260512","doi-asserted-by":"crossref","first-page":"1\u201312","DOI":"10.1016\/j.canlet.2020.02.002","article-title":"Immunotherapy for glioma: current management and future application","volume":"476","author":"Xu","year":"2020","journal-title":"Cancer Lett"},{"key":"R239-20260512","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41419-020-2696-5","article-title":"Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis"},{"key":"R240-20260512","doi-asserted-by":"crossref","first-page":"279\u201399","DOI":"10.1038\/s41571-019-0320-3","article-title":"Current approaches to the management of brain metastases","volume":"17","author":"Suh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R241-20260512","doi-asserted-by":"crossref","first-page":"555\u201361","DOI":"10.1007\/s11060-024-04754-8","article-title":"Patterns of brain metastases response to immunotherapy with pembrolizumab","volume":"169","author":"Mahajan","year":"2024","journal-title":"J Neuro-oncol"},{"key":"R242-20260512","doi-asserted-by":"crossref","first-page":"1113\u201318","DOI":"10.1016\/j.ijrobp.2019.08.053","article-title":"Frequent use of local therapy underscores need for multidisciplinary care in the management of patients with melanoma brain metastases treated with PD-1 inhibitors","volume":"105","author":"Qian","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R243-20260512","doi-asserted-by":"crossref","first-page":"52\u201360","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"key":"R244-20260512","doi-asserted-by":"crossref","first-page":"149\u201363","DOI":"10.1016\/j.ejca.2021.07.028","article-title":"Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases","volume":"156","author":"Hilbers","year":"2021","journal-title":"Eur J Cancer"},{"key":"R245-20260512","doi-asserted-by":"crossref","first-page":"672\u201381","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"R246-20260512","doi-asserted-by":"crossref","first-page":"722\u201330","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"New Engl J Med"},{"key":"R247-20260512","doi-asserted-by":"crossref","first-page":"160\u201365","DOI":"10.1159\/000380890","article-title":"Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients","volume":"38","author":"Li","year":"2015","journal-title":"Oncol Res Treat"},{"key":"R248-20260512","doi-asserted-by":"crossref","first-page":"134\u201343","DOI":"10.1158\/2326-6066.CIR-13-0007","article-title":"Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study","volume":"1","author":"Poli","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"R249-20260512","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1471-2407-6-225","article-title":"Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer","volume":"6","author":"Orlando","year":"2006","journal-title":"BMC Cancer"},{"key":"R250-20260512","doi-asserted-by":"crossref","first-page":"459\u201365","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"R251-20260512","doi-asserted-by":"crossref","first-page":"2008\u201316","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol"},{"key":"R252-20260512","doi-asserted-by":"crossref","first-page":"84\u201394","DOI":"10.1158\/1078-0432.CCR-21-0878","article-title":"A randomized phase II study of nivolumab monotherapy or nivolumab combined with Ipilimumab in patients with advanced gastrointestinal stromal tumors","volume":"28","author":"Singh","year":"2022","journal-title":"Clin Cancer Res: Off J American Assoc Cancer Res"},{"key":"R253-20260512","doi-asserted-by":"crossref","first-page":"503\u201310","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"R254-20260512","doi-asserted-by":"crossref","first-page":"809\u201322","DOI":"10.1016\/j.trecan.2021.02.003","article-title":"Next-generation immunotherapies for brain metastatic cancers","volume":"7","author":"L\u00f3pez V\u00e1zquez","year":"2021","journal-title":"Trends Cancer"},{"key":"R255-20260512","doi-asserted-by":"crossref","first-page":"E6157","DOI":"10.1073\/pnas.1700363114","article-title":"Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas","volume":"114","author":"Du","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"R256-20260512","doi-asserted-by":"crossref","first-page":"2410\u201318","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"R257-20260512","doi-asserted-by":"crossref","first-page":"587\u201397","DOI":"10.1016\/j.nurt.2009.04.013","article-title":"Biology and treatment of primary central nervous system lymphoma","volume":"6","author":"Algazi","year":"2009","journal-title":"Neurother: J Am Soc Expl Neuro Ther"},{"key":"R258-20260512","first-page":"218\u201321","article-title":"Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy","volume":"110","author":"Mercadal","year":"2025","journal-title":"Haematologica"},{"key":"R259-20260512","doi-asserted-by":"crossref","first-page":"3485\u201390","DOI":"10.3324\/haematol.2023.282875","article-title":"CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes","volume":"108","author":"Lacan","year":"2023","journal-title":"Haematologica"},{"key":"R260-20260512","doi-asserted-by":"crossref","first-page":"2306\u201315","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"R261-20260512","doi-asserted-by":"crossref","first-page":"4059\u201363","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"key":"R262-20260512","doi-asserted-by":"crossref","first-page":"590\u201396","DOI":"10.4143\/crt.2024.531","article-title":"Nivolumab in relapsed or refractory primary central nervous system lymphoma: multicenter, retrospective study","volume":"57","author":"Yi","year":"2025","journal-title":"Cancer Res Treat: Off J Korean Cancer Assoc"},{"key":"R263-20260512","doi-asserted-by":"crossref","first-page":"3071\u201373","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"R264-20260512","doi-asserted-by":"crossref","first-page":"575\u201381","DOI":"10.1093\/neuonc\/nov253","article-title":"Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma","volume":"18","author":"Cheah","year":"2016","journal-title":"Neuro-oncol"},{"key":"R265-20260512","doi-asserted-by":"crossref","first-page":"25783\u201390","DOI":"10.18632\/oncotarget.8370","article-title":"Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy","volume":"7","author":"Qian","year":"2016","journal-title":"Oncotarget"},{"key":"R266-20260512","doi-asserted-by":"crossref","first-page":"3061\u201368","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"key":"R267-20260512","doi-asserted-by":"crossref","first-page":"1146\u201355","DOI":"10.1158\/1078-0432.CCR-11-0625","article-title":"Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI","volume":"18","author":"Wieduwilt","year":"2012","journal-title":"Clin Cancer Res: Off J American Assoc Cancer Res"},{"key":"R268-20260512","doi-asserted-by":"crossref","first-page":"783\u201384","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"New Engl J Med"},{"key":"R269-20260512","doi-asserted-by":"crossref","first-page":"691\u2013702","DOI":"10.1111\/bpa.12811","article-title":"The molecular biology of medulloblastoma metastasis","volume":"30","author":"Van Ommeren","year":"2020","journal-title":"Brain Pathol (Zurich, Switzerland)"},{"key":"R270-20260512","doi-asserted-by":"crossref","first-page":"813\u201320","DOI":"10.1016\/S1470-2045(06)70867-1","article-title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial","volume":"7","author":"Gajjar","year":"2006","journal-title":"Lancet Oncol"},{"key":"R271-20260512","doi-asserted-by":"crossref","first-page":"465\u201372","DOI":"10.1007\/s00401-011-0922-z","article-title":"Molecular subgroups of medulloblastoma: the current consensus","volume":"123","author":"Taylor","year":"2012","journal-title":"Acta Neuropathol"},{"key":"R272-20260512","doi-asserted-by":"crossref","first-page":"e26754","DOI":"10.1002\/pbc.26754","article-title":"A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma","volume":"65","author":"Kramer","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R273-20260512","doi-asserted-by":"crossref","first-page":"245\u201349","DOI":"10.1007\/s11060-015-1788-z","article-title":"Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy","volume":"123","author":"Kramer","year":"2015","journal-title":"J Neuro-oncol"},{"key":"R274-20260512","doi-asserted-by":"crossref","first-page":"519\u201325","DOI":"10.1002\/pbc.22319","article-title":"Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours","volume":"54","author":"Ardon","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R275-20260512","doi-asserted-by":"crossref","first-page":"720\u201331","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"R276-20260512","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.3390\/ijms25137174","article-title":"CAR-T cells therapy in glioblastoma: a systematic review on molecular targets and treatment strategies","volume":"25","author":"Agosti","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R277-20260512","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/vaccines12060655","article-title":"Glioblastoma vaccines as promising immune-therapeutics: challenges and Current Status","volume":"12","author":"Squalli Houssaini","year":"2024","journal-title":"Vaccines"},{"key":"R278-20260512","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","article-title":"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau","year":"2018","journal-title":"J Transl Med"},{"key":"R279-20260512","doi-asserted-by":"crossref","first-page":"57\u201377","DOI":"10.2147\/ITT.S198162","article-title":"Immunotherapy for medulloblastoma: current perspectives","volume":"9","author":"Kabir","year":"2020","journal-title":"ImmunoTargets Ther"},{"key":"R280-20260512","doi-asserted-by":"crossref","first-page":"225\u201348","DOI":"10.15171\/bi.2016.30","article-title":"Blood-brain barrier transport machineries and targeted therapy of brain diseases","volume":"6","author":"Barar","year":"2016","journal-title":"BioImpacts: BI"},{"key":"R281-20260512","doi-asserted-by":"crossref","first-page":"357\u201381","DOI":"10.1080\/17512433.2021.1887729","article-title":"Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier","volume":"14","author":"Omidi","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R282-20260512","doi-asserted-by":"crossref","first-page":"43271","DOI":"10.1038\/srep43271","article-title":"Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma","volume":"7","author":"Ramachandran","year":"2017","journal-title":"Sci Rep"},{"key":"R283-20260512","doi-asserted-by":"crossref","first-page":"576\u201388","DOI":"10.1016\/j.jconrel.2023.11.009","article-title":"Implantable magnetically-actuated capsule for on-demand delivery","volume":"364","author":"Zheng","year":"2023","journal-title":"J Control Release"},{"key":"R284-20260512","doi-asserted-by":"crossref","first-page":"1704\u201316\u201316","DOI":"10.1038\/s44321-024-00091-5","article-title":"Minimally-invasive implantable device enhances brain cancer suppression","volume":"16","author":"Cao","year":"2024","journal-title":"EMBO Mol Med"},{"key":"R285-20260512","doi-asserted-by":"crossref","first-page":"1093\u2013104","DOI":"10.1016\/j.ultrasmedbio.2007.12.015","article-title":"Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium","volume":"34","author":"Sheikov","year":"2008","journal-title":"Ultrasound Med Biol"},{"key":"R286-20260512","doi-asserted-by":"crossref","first-page":"6192\u2013205","DOI":"10.1039\/C8NR08970A","article-title":"Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors","volume":"11","author":"Hettiarachchi","year":"2019","journal-title":"Nanoscale"},{"key":"R287-20260512","doi-asserted-by":"crossref","first-page":"907\u201320","DOI":"10.1517\/17425255.2015.1028917","article-title":"Mechanisms and therapeutic potential of inhibiting drug efflux transporters","volume":"11","author":"Klukovits","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R288-20260512","doi-asserted-by":"crossref","first-page":"986\u20131001","DOI":"10.20892\/j.issn.2095-3941.2020.0128","article-title":"HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model","volume":"17","author":"Zeng","year":"2020","journal-title":"Cancer Biol Med"},{"key":"R289-20260512","doi-asserted-by":"crossref","first-page":"e1006351","DOI":"10.1371\/journal.ppat.1006351","article-title":"Toxoplasma gondii: entry, association, and physiological influence on the central nervous system","volume":"13","author":"Mendez","year":"2017","journal-title":"PLoS Pathog"},{"key":"R290-20260512","doi-asserted-by":"crossref","first-page":"2051\u201372","DOI":"10.1038\/s41564-024-01750-6","article-title":"Engineering Toxoplasma gondii secretion systems for intracellular delivery of multiple large therapeutic proteins to neurons","volume":"9","author":"Bracha","year":"2024","journal-title":"Nat Microbiol"},{"key":"R291-20260512","doi-asserted-by":"crossref","first-page":"1709\u201320","DOI":"10.1111\/cns.14217","article-title":"Advances in research on immune escape mechanism of glioma","volume":"29","author":"Guo","year":"2023","journal-title":"CNS Neurosci Ther"},{"key":"R292-20260512","doi-asserted-by":"crossref","first-page":"e002451","DOI":"10.1136\/jitc-2021-002451","article-title":"MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas","volume":"9","author":"Wang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R293-20260512","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1038\/s41467-022-32311-2","article-title":"Circular EZH2-encoded EZH2-92aa mediates immune evasion in glioblastoma via inhibition of surface NKG2D ligands","volume":"13","author":"Zhong","year":"2022","journal-title":"Nat Commun"},{"key":"R294-20260512","doi-asserted-by":"crossref","first-page":"2105\u201315","DOI":"10.3892\/ijo.2016.3704","article-title":"Macrophage migration inhibitory factor enhances autophagy by regulating ROCK1 activity and contributes to the escape of dendritic cell surveillance in glioblastoma","volume":"49","author":"Xu","year":"2016","journal-title":"Int J Oncol"},{"key":"R295-20260512","doi-asserted-by":"crossref","first-page":"1499\u2013509","DOI":"10.1158\/1535-7163.MCT-22-0201","article-title":"A novel EGFRvIII T-Cell Bispecific antibody for the treatment of glioblastoma","volume":"21","author":"Iurlaro","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"R296-20260512","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41467-025-56547-w","article-title":"Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen","volume":"16","author":"Chih","year":"2025","journal-title":"Nat Commun"},{"key":"R297-20260512","doi-asserted-by":"crossref","first-page":"ii46","DOI":"10.1093\/neuonc\/noad137.145","article-title":"P06.05.A INTRACEREBROVENTRICULAR TCR-TRANSGENIC T CELL THERAPY TO TREAT GLIOBLASTOMA (INVENT4GB)","volume":"25","author":"Bunse","year":"2023","journal-title":"Neuro-oncol"},{"key":"R298-20260512","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1016\/j.cell.2025.03.041","article-title":"Immunotherapy-related cognitive impairment after CAR T cell therapy in mice","volume":"188","author":"Geraghty","year":"2025","journal-title":"Cell"},{"key":"R299-20260512","doi-asserted-by":"crossref","first-page":"6036\u201345","DOI":"10.1158\/0008-5472.CAN-13-0186","article-title":"Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons","volume":"73","author":"Sanborn","year":"2013","journal-title":"Cancer Res"},{"key":"R300-20260512","doi-asserted-by":"crossref","first-page":"575\u201390","DOI":"10.1158\/2159-8290.CD-20-1474","article-title":"Diffuse glioma heterogeneity and Its Therapeutic Implications","volume":"11","author":"Nicholson","year":"2021","journal-title":"Cancer Discov"},{"key":"R301-20260512","doi-asserted-by":"crossref","first-page":"153\u201366","DOI":"10.1007\/s00401-018-1849-4","article-title":"Novel, improved grading system(s) for IDH-mutant astrocytic gliomas","volume":"136","author":"Shirahata","year":"2018","journal-title":"Acta Neuropathol"},{"key":"R302-20260512","first-page":"100082","article-title":"Transparency in the reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:04:27Z","timestamp":1778587467000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":301,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002993","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"2025-04-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}